{"id":"hmpl-760","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HMPL-760 selectively targets FGFR kinases, which are frequently dysregulated in various solid tumors through mutations, amplifications, or translocations. By inhibiting FGFR-mediated signaling pathways, the drug suppresses tumor cell proliferation and survival in FGFR-dependent cancers. This mechanism is particularly relevant in tumors with FGFR alterations where the pathway drives oncogenic growth.","oneSentence":"HMPL-760 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:01.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cholangiocarcinoma with FGFR2 fusion or rearrangement"},{"name":"Urothelial carcinoma with FGFR alterations"},{"name":"Other solid tumors with FGFR genetic alterations"}]},"trialDetails":[{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT06601504","phase":"PHASE2","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2024-11-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":61},{"nctId":"NCT05190068","phase":"PHASE1","title":"HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-01-04","conditions":"B-Cell Non-Hodgkin's Lymphoma","enrollment":89},{"nctId":"NCT05176691","phase":"PHASE1","title":"HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL","status":"WITHDRAWN","sponsor":"Hutchmed","startDate":"2022-02-15","conditions":"CLL/SLL, NHL, MCL","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HMPL-760","genericName":"HMPL-760","companyName":"Hutchmed","companyId":"hutchmed","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HMPL-760 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for Cholangiocarcinoma with FGFR2 fusion or rearrangement, Urothelial carcinoma with FGFR alterations, Other solid tumors with FGFR genetic alterations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}